NCT02993705 (MITO 26) is a Phase 2 clinical trial of Trabectedin in Carcinosarcoma, Ovarian, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT02993705?

NCT02993705 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT02993705?

Interventions in NCT02993705: Trabectedin.

What condition does NCT02993705 study?

NCT02993705 studies Carcinosarcoma, Ovarian, Carcinosarcomas Uterine.

Is NCT02993705 still recruiting?

NCT02993705 is currently completed. Last updated 25 August 2021.

Last reviewed 2021-08-25 · How we verify

NCT02993705: MITO 26

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)

Completed Phase 2 Last updated 25 August 2021

What this trial tests

Phase 2 trial testing Trabectedin in Carcinosarcoma, Ovarian in 45 participants. Completed in 13 November 2019.

Timeline

22 February 2017

Primary endpoint
13 November 2019

13 November 2019

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	22 February 2017
Primary completion	13 November 2019
Estimated completion	13 November 2019
Sites	1 location across Italy

Drugs / interventions tested

Trabectedin (TRABECTEDIN) — full drug profile →

Conditions studied

Carcinosarcoma, Ovarian — all drugs for Carcinosarcoma, Ovarian →
Carcinosarcomas Uterine — all drugs for Carcinosarcomas Uterine →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

Adults 18 to 100, female only, with Carcinosarcoma, Ovarian or Carcinosarcomas Uterine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity. Disease response evaluation will be assessed every 9 weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8
DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.
Ovejero-Sánchez M, González-Sarmiento R, Herrero AB. · · 2023 · cited 16× · PMID 36672401 · DOI 10.3390/cancers15020448
Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox.
Moufarrij S, O'Cearbhaill RE. · · 2023 · cited 14× · PMID 38248092 · DOI 10.3390/curroncol31010007

Verify or expand the search:

Other trials of Trabectedin

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07076186 — Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS · Phase 2 · recruiting
NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W · Phase 2, PHASE3 · active not recruiting
NCT04794127 — Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. · Phase 2 · completed
NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02993705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 25 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02993705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing